Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 2
2018 6
2019 2
2020 7
2021 4
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Gastric Myeloid Sarcoma Mimicking a Scirrhous Gastric Cancer.
Taminishi-Katsuragawa Y, Shimura Y, Inoue Y, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Kobayashi T, Takeda-Miyata N, Nishimura A, Takatsuka K, Kuroda J. Taminishi-Katsuragawa Y, et al. Among authors: matsumura kimoto y. Intern Med. 2022 Apr 15;61(8):1231-1235. doi: 10.2169/internalmedicine.7986-21. Epub 2021 Oct 5. Intern Med. 2022. PMID: 34615821 Free PMC article.
The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. Isa R, et al. Among authors: matsumura kimoto y. Int J Mol Sci. 2022 Mar 8;23(6):2919. doi: 10.3390/ijms23062919. Int J Mol Sci. 2022. PMID: 35328342 Free PMC article.
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. Nishiyama D, et al. Among authors: matsumura kimoto y. Int J Hematol. 2021 Mar;113(3):381-394. doi: 10.1007/s12185-020-03027-0. Epub 2020 Oct 23. Int J Hematol. 2021. PMID: 33095415
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D, Fujibayashi Y, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, Gütschow M, Kuroda J. Kuwahara-Ota S, et al. Among authors: matsumura kimoto y. Br J Haematol. 2020 Dec;191(5):784-795. doi: 10.1111/bjh.16881. Epub 2020 Jun 19. Br J Haematol. 2020. PMID: 32558939 Free article.
BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.
Tsukamoto T, Nakahata S, Sato R, Kanai A, Nakano M, Chinen Y, Maegawa-Matsui S, Matsumura-Kimoto Y, Takimoto-Shimomura T, Mizuno Y, Kuwahara-Ota S, Kawaji Y, Taniwaki M, Inaba T, Tashiro K, Morishita K, Kuroda J. Tsukamoto T, et al. Among authors: matsumura kimoto y. Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):77-89. doi: 10.21873/cgp.20169. Cancer Genomics Proteomics. 2020. PMID: 31882553 Free PMC article.
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: matsumura kimoto y. Cancer Rep (Hoboken). 2022 Feb;5(2):e1476. doi: 10.1002/cnr2.1476. Epub 2021 Jun 14. Cancer Rep (Hoboken). 2022. PMID: 34124862 Free PMC article.
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y, Shimura Y, Kobayashi T, Horiike S, Kuroda J. Sakiyama E, et al. Among authors: matsumura kimoto y. Infect Drug Resist. 2020 Apr 8;13:1017-1021. doi: 10.2147/IDR.S249030. eCollection 2020. Infect Drug Resist. 2020. PMID: 32308443 Free PMC article.
miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma.
Kawaji-Kanayama Y, Tsukamoto T, Nakano M, Tokuda Y, Nagata H, Mizuhara K, Katsuragawa-Taminishi Y, Isa R, Fujino T, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Tashiro K, Kuroda J. Kawaji-Kanayama Y, et al. Among authors: matsumura kimoto y. Cancer Sci. 2024 Feb;115(2):452-464. doi: 10.1111/cas.16027. Epub 2023 Dec 5. Cancer Sci. 2024. PMID: 38050664 Free PMC article.
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: matsumura kimoto y. Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 2022 Jan 24. Int J Hematol. 2022. PMID: 35072907
Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti-SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms.
Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J. Onishi A, et al. Among authors: matsumura kimoto y. Infect Drug Resist. 2023 Jan 25;16:509-519. doi: 10.2147/IDR.S396271. eCollection 2023. Infect Drug Resist. 2023. PMID: 36721633 Free PMC article.
25 results